top
Please input keywords
Order
*Country
日本
アメリカ
中国
オーストラリア
シンガポール
イギリス
フランス
ドイツ
スイス
イタリア
カナダ
韓国
オランダ
ベルギー
スウェーデン
その他
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hIL33 mice
Strain Name
C57BL/6-IL33tm1(hIL33)Bcgen/Bcgen
Common Name  B-hIL33 mice
Background C57BL/6 Catalog number  110055
Related Genes 
interleukin 33; IL1F11
NCBI Gene ID
77125

Protein expression analysis


from clipboard

Antibody efficacy evaluation

Model schematic and antibody evaluation scheme

from clipboard·

·Blue arrows: time for sensitization and challenge; 

·Red arrows: time for drug administration.



from clipboard

Antibody efficacy evaluation

The proportion of BALF immune cells in acute mouse asthma model


from clipboard


Antibody efficacy evaluation

The number of BALF immune cells in acute mouse asthma model


from clipboard


BALF immune cell profiles in acute mouse asthma model


BALF Immune cells were isolated from B-hIL33 mice (n=5). The number of eosinophils were deterimined by flow cytometry in acute asthma mice treated with or without etokimab anolog. Treatment of etokimab analog almost completely abolished the inflammatory cells in homozygous B-hIL33 mice as opposed to in untreated mice.


Antibody efficacy evaluation

IgE production in mouse asthma model


from clipboard

IgE production


Serum was collected at the study endpoint. IgE levels responded to OVA-specific antibody were analyzed. 

The results show that the levels of IgE in mice treated with etokimab is much lower than that in untreated mice. 


H&E stain in mouse asthma model

from clipboard
Airways from B-hIL33 mice exposed to PBS aerosols did not show any inflammation. OVA exposure resulted in a significant increase in peribronchial and perivascular inflammatory infiltrates, as well as increase in the level of mucus secretion. A reduction in inflammatory infiltrates and mucus secretion was observed in mice treated with etokimab analog. 

Summary


1.Gene expression: human IL33 was detectable in the homozygous B-hIL33 mice.
2.Protein expression: human IL33 was detectable in the homozygous B-hIL33 mice.
3.Analysis of leukocyte subpopulation: the expression profile of leukocytes subpopulation in homozygous B-hIL33 mice is similar to that in the C57BL/6 mice.
4.Antibody efficacy evaluation: OVA-induced acute asthma model has been successfully established as indicated by increased eosinophilia, IgE production. This model is further validated with etokimab, which greatly reduced the inflammatory cells and IgE.
5.B-hIL33 mice is a validated, valuable tool for in vivo efficacy evaluation of anti-human IL33 antibodies.